Quarterly report · Q1
4583.TEDINET S100TEU8
Period2024-01-01 → 2024-03-31
Filed2024-05-14
StandardJapan GAAP
ConsolidatedNo
Data checks10 of 10 passed
Key figures · 32
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥130m | 2024-01-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥682m | 2023-01-01 → 2023-12-31 | Standalone | Net sales (5-year summary) |
| Revenue | ¥169m | 2023-01-01 → 2023-03-31 | Standalone | Net sales |
| Operating income | −¥322m | 2024-01-01 → 2024-03-31 | Standalone | Operating income |
| Operating income | −¥226m | 2023-01-01 → 2023-03-31 | Standalone | Operating income |
| Ordinary income | −¥303m | 2024-01-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥1.2bn | 2023-01-01 → 2023-12-31 | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥227m | 2023-01-01 → 2023-03-31 | Standalone | Ordinary income |
| Profit before tax | −¥303m | 2024-01-01 → 2024-03-31 | Standalone | Income before income taxes |
| Profit before tax | −¥226m | 2023-01-01 → 2023-03-31 | Standalone | Income before income taxes |
| Net income | −¥304m | 2024-01-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | −¥1.2bn | 2023-01-01 → 2023-12-31 | Standalone | Net income loss (5-year summary) |
| Net income | −¥228m | 2023-01-01 → 2023-03-31 | Standalone | Profit loss |
| Total assets | ¥1.8bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥1.8bn | at 2023-12-31 | Standalone | Assets |
| Total assets | ¥2.1bn | at 2023-03-31 | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥506m | at 2024-03-31 | Standalone | Liabilities |
| Total liabilities | ¥594m | at 2023-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥1.2bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥1.2bn | at 2023-12-31 | Standalone | Net assets |
| Net assets / equity | ¥1.6bn | at 2023-03-31 | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.3bn | at 2024-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.3bn | at 2023-12-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥-5.6 | 2024-01-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-24.62 | 2023-01-01 → 2023-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-4.7 | 2023-01-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| Equity ratio | 70.4% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 65.1% | at 2023-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 74.3% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 55,720,600 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 52,640,200 | at 2023-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 48,423,500 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 16
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment profit | 2024-01-01 → 2024-03-31 | −¥133m |
| jpcrp040300-q1r_E26096-000Drug Discovery And Developmentreportable segment | segment profit | 2024-01-01 → 2024-03-31 | −¥246m |
| jpcrp040300-q1r_E26096-000Drug Discovery Supportreportable segment | revenue | 2024-01-01 → 2024-03-31 | ¥130m |
| jpcrp040300-q1r_E26096-000Drug Discovery Supportreportable segment | revenue external | 2024-01-01 → 2024-03-31 | ¥130m |
| jpcrp040300-q1r_E26096-000Drug Discovery Supportreportable segment | segment profit | 2024-01-01 → 2024-03-31 | ¥57m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-01-01 → 2024-03-31 | ¥130m |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-01-01 → 2024-03-31 | ¥130m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-01-01 → 2024-03-31 | −¥189m |
| Reconciling Itemsreconciling | segment profit | 2023-01-01 → 2023-03-31 | −¥128m |
| jpcrp040300-q1r_E26096-000Drug Discovery And Developmentreportable segment | segment profit | 2023-01-01 → 2023-03-31 | −¥194m |
| jpcrp040300-q1r_E26096-000Drug Discovery Supportreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥169m |
| jpcrp040300-q1r_E26096-000Drug Discovery Supportreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥169m |
| jpcrp040300-q1r_E26096-000Drug Discovery Supportreportable segment | segment profit | 2023-01-01 → 2023-03-31 | ¥96m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-01-01 → 2023-03-31 | ¥169m |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-01-01 → 2023-03-31 | ¥169m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-01-01 → 2023-03-31 | −¥98m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 321
| Item | Context | Value | Unit |
|---|---|---|---|
| Transactions with other segments | Prior1YTDDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_NonConsolidatedMember | － | JPY |
| Net sales | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q1r_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember | － | JPY |
| Net sales | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q1r_E26096-000DrugDiscoverySupportReportableSegmentsMember | 169404000 | JPY |
| Net sales | Prior1YTDDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember | 169404000 | JPY |
| Net sales | Prior1YTDDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Net sales | Prior1YTDDuration_NonConsolidatedMember | 169404000 | JPY |
| Operating income | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q1r_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember | -193637000 | JPY |
| Operating income | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q1r_E26096-000DrugDiscoverySupportReportableSegmentsMember | 95940000 | JPY |
| Operating income | Prior1YTDDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember | -97697000 | JPY |
| Operating income | Prior1YTDDuration_NonConsolidatedMember_ReconcilingItemsMember | -128297000 | JPY |
| Operating income | Prior1YTDDuration_NonConsolidatedMember | -225994000 | JPY |
| Revenues from external customers | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q1r_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q1r_E26096-000DrugDiscoverySupportReportableSegmentsMember | 129644000 | JPY |
| Revenues from external customers | CurrentYTDDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember | 129644000 | JPY |
| Revenues from external customers | CurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration_NonConsolidatedMember | 129644000 | JPY |
| Transactions with other segments | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q1r_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q1r_E26096-000DrugDiscoverySupportReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_NonConsolidatedMember | － | JPY |
| Net sales | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q1r_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember | － | JPY |
| Net sales | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q1r_E26096-000DrugDiscoverySupportReportableSegmentsMember | 129644000 | JPY |
| Net sales | CurrentYTDDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember | 129644000 | JPY |
| Net sales | CurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Net sales | CurrentYTDDuration_NonConsolidatedMember | 129644000 | JPY |
| Operating income | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q1r_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember | -246405000 | JPY |
| Operating income | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q1r_E26096-000DrugDiscoverySupportReportableSegmentsMember | 56998000 | JPY |
| Operating income | CurrentYTDDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember | -189406000 | JPY |
| Operating income | CurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember | -132749000 | JPY |
| Operating income | CurrentYTDDuration_NonConsolidatedMember | -322155000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2024-05-14 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第21期第１四半期（自 2024年１月１日 至 2024年３月31日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社カイオム・バイオサイエンス | |
| Company name in english cover page | FilingDateInstant | Chiome Bioscience Inc. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 小林 茂 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都渋谷区本町三丁目12番１号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 03-6383-3561 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)取締役経営企画室長 美女平 在彦 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都渋谷区本町三丁目12番１号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 03-6383-3561 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)取締役経営企画室長 美女平 在彦 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E26096 | |
| Fund code | FilingDateInstant | － |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 10 of 10 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |